METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours.
Ecancermedicalscience
; 16: 1369, 2022.
Article
in En
| MEDLINE
| ID: mdl-35685961
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
/
Risk_factors_studies
Language:
En
Journal:
Ecancermedicalscience
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: